Cite
HARVARD Citation
Osumi, H. et al. (2018). Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer. Cancer science. 109 (8), pp. 2567-2575. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Osumi, H. et al. (2018). Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer. Cancer science. 109 (8), pp. 2567-2575. [Online].